Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02985632

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Single-dose Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Status
Withdrawn
Phase
Phase 1
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Accepted

Summary

An oral dose of BMS-986141 administered in Hepatic Impairment and Healthy Participants to evaluate pharmacokinetics in this patient population.

Conditions

Interventions

TypeNameDescription
DRUGBMS-986141

Timeline

Start date
2017-01-11
Primary completion
2017-05-18
Completion
2017-07-07
First posted
2016-12-07
Last updated
2017-02-06

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02985632. Inclusion in this directory is not an endorsement.